Research progress of perfluorohexyloctane eyedrop in meibomian gland dysfunction-associated dry eye
10.3980/j.issn.1672-5123.2026.8.08
- VernacularTitle:全氟己基辛烷滴眼液在睑板腺功能障碍相关性干眼中的研究进展
- Author:
Hongyue YU
1
;
Bin SUN
1
;
Yan LI
1
;
Xiaodan LI
1
;
Meng XIN
1
Author Information
1. Department of Ophthalmology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai 264100, Shandong Province, China
- Publication Type:Journal Article
- Keywords:
dry eye disease;
perfluorohexyloctane;
lipid abnormality type dry eye;
meibomian gland dysfunction;
research progress
- From:
International Eye Science
2026;26(8):1354-1358
- CountryChina
- Language:Chinese
-
Abstract:
Dry eye disease(DED)is a multifactorial ocular surface disorder characterized by the loss of tear film homeostasis among which evaporative DED associated with meibomian gland dysfunction(MGD)accounts for up to 86%, and traditional drugs fail to effectively target the core pathological mechanism. As a new type of anhydrous and preservative-free eye drops approved by the FDA, perfluorohexyloctane has a unique amphiphilic structure, which can form an artificial lipid monolayer at the air-liquid interface of the tear film. It exerts its therapeutic effects by inhibiting tear evaporation, stabilizing the tear film, unclogging meibomian gland orifices, and promoting corneal oxygen supply. This drug can not only serve as a first-line treatment option for evaporative DED but also be combined with other drugs for personalized treatment. This review summarizes the mechanism of action, pharmacological properties, clinical efficacy, and safety of perfluorohexyloctane eye drops, and further elaborate on its application value in complex types of DED and patients with other concurrent ocular surface diseases, aiming to provide more evidence support for the precise treatment of DED.
